List of Excipients in Branded Drug TRIMETHOPRIM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Golden State Medical Supply Inc	TRIMETHOPRIM	trimethoprim	51407-257	CELLULOSE, MICROCRYSTALLINE
Golden State Medical Supply Inc	TRIMETHOPRIM	trimethoprim	51407-257	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Golden State Medical Supply Inc	TRIMETHOPRIM	trimethoprim	51407-257	MAGNESIUM STEARATE
Golden State Medical Supply Inc	TRIMETHOPRIM	trimethoprim	51407-257	SILICON DIOXIDE

Generic Drugs Containing TRIMETHOPRIM

Company	Ingredient	NDC	Excipient
Novel Laboratories Inc	trimethoprim	40032-330	CELLULOSE, MICROCRYSTALLINE
Novel Laboratories Inc	trimethoprim	40032-330	LACTOSE MONOHYDRATE
Novel Laboratories Inc	trimethoprim	40032-330	MAGNESIUM STEARATE
Novel Laboratories Inc	trimethoprim	40032-330	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in TRIMETHOPRIM?

# Of NDCs	Excipient
4	ANHYDROUS LACTOSE
6	CELLULOSE, MICROCRYSTALLINE
4	LACTOSE MONOHYDRATE
8	MAGNESIUM STEARATE

Trimethoprim Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Trimethoprim is an established, low-cost antibacterial with limited remaining value in the active pharmaceutical ingredient itself. Commercial opportunity lies in differentiated dosage forms, pediatric acceptability, improved suspension stability, renal-dose flexibility, combination products, and supply-chain economics. The strongest excipient strategies address trimethoprim’s poor aqueous solubility, bitter taste, dose flexibility, physical stability, and patient adherence.

What is the current commercial status of trimethoprim?

Trimethoprim is an established dihydrofolate reductase inhibitor used primarily for urinary tract infections and, in combination with sulfamethoxazole, for several bacterial infections. It is available as a standalone oral product and as part of the trimethoprim-sulfamethoxazole combination.

Attribute	Trimethoprim
Active ingredient	Trimethoprim
Drug class	Dihydrofolate reductase inhibitor
Main standalone uses	Urinary tract infections and susceptible bacterial infections
Common combination	Trimethoprim-sulfamethoxazole
Common dosage forms	Tablets, oral solution or suspension, injectable products in some markets
Core formulation issue	Low aqueous solubility and strong bitterness
Primary commercial market	Generic and institutional
Core patent position	Legacy molecule with no meaningful remaining composition-of-matter exclusivity
Main competitive factors	Price, supply reliability, dosage-form usability, pediatric acceptance, and regulatory execution

The commercial market is mature. A new product is unlikely to command a premium solely because it contains trimethoprim. A premium requires a measurable product advantage, such as a ready-to-use pediatric liquid, a high-stability suspension, simplified renal dosing, or a combination product designed for a defined treatment setting.

FDA-approved trimethoprim products and trimethoprim-sulfamethoxazole products establish broad precedent for conventional pharmaceutical excipients and oral dosage forms. Product-specific composition should still be assessed against current FDA inactive-ingredient databases and the relevant marketed reference product before development decisions are made (U.S. Food and Drug Administration, n.d.-a).

What excipient problems must a trimethoprim formulation solve?

The principal formulation constraints are solubility, bitterness, suspension stability, dose uniformity, and patient acceptability.

Low aqueous solubility

Trimethoprim is a weak base with limited water solubility at neutral pH. This creates challenges for liquid dosage forms and can produce slow dissolution from tablets if particle size, wetting, and granulation are not controlled.

Potential formulation responses include:

• Particle-size reduction
• Wetting agents
• Hydrophilic binders
• pH modification
• Complexation
• Amorphous or co-processed solid dispersions
• Salt or cosolvent systems, where regulatory and stability profiles support their use

The lowest-risk approach is usually an immediate-release tablet using conventional disintegrants and dissolution-enhancing excipients. More complex solubilization systems are more suitable for liquid products or products with a defined bioavailability advantage.

Strong bitterness

Bitterness is a major barrier to pediatric and geriatric liquid products. Taste masking should be designed around the exposure profile of trimethoprim during administration. A flavor system alone is unlikely to solve the problem if the drug dissolves rapidly in the mouth.

Potential approaches include:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Lipid or wax coating
• Cyclodextrin complexation
• Sweeteners and high-intensity sweetener combinations
• Flavor systems selected for the target age group
• Viscosity enhancement to reduce immediate oral contact

Ion-exchange resin complexes and polymer-coated particles can provide stronger taste masking than flavoring alone. They also create added risks involving drug release, particle-size distribution, content uniformity, and scale-up.

Physical instability in suspensions

A trimethoprim suspension must maintain dose uniformity throughout the labeled in-use period. Key failure modes include sedimentation, caking, crystal growth, viscosity drift, microbial contamination, and nonuniform redispersion.

Useful excipient classes include:

• Suspending agents such as xanthan gum, microcrystalline cellulose and carboxymethylcellulose systems, or other approved polymers
• Wetting agents
• Flocculating agents
• Buffers
• Preservatives
• Sweeteners and flavors
• Antioxidants where justified by the formulation
• Chelating agents where trace-metal sensitivity is demonstrated

A structured, easily redispersible suspension is commercially preferable to a high-viscosity product that resists pouring or dosing. Viscosity should support dose uniformity without making administration difficult through oral syringes.

What excipient strategy is appropriate for trimethoprim tablets?

For immediate-release tablets, the commercial objective is usually low cost, robust manufacturing, rapid disintegration, and consistent dissolution.

Conventional immediate-release tablet

A conventional tablet may use:

• Lactose, microcrystalline cellulose, or dibasic calcium phosphate as diluent
• Povidone or copovidone as binder
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as disintegrant
• Colloidal silicon dioxide as glidant
• Magnesium stearate or another lubricant
• Film-coating polymers, plasticizers, pigments, and opacifiers

The principal development risk is excessive hydrophobic lubrication or inadequate disintegration, which can slow dissolution. Magnesium stearate concentration and blending time require close control, especially when trimethoprim particle properties vary between API suppliers.

Direct compression may reduce processing cost, but wet granulation can improve flow, content uniformity, and compaction. The preferred process depends on dose strength, API particle morphology, and the target tablet weight.

Orally disintegrating or dispersible tablet

An orally disintegrating or dispersible trimethoprim tablet could target:

• Children who cannot swallow conventional tablets
• Older adults with dysphagia
• Patients with limited access to water
• Institutional care settings
• Emergency or travel use

The main technical issue remains bitterness. A rapidly disintegrating tablet without adequate taste masking may reduce adherence rather than improve it. A compressed taste-masked multiparticulate system may offer a better balance between disintegration and palatability.

The regulatory pathway would require evidence that the product meets the applicable dissolution, dose-uniformity, stability, and bioequivalence requirements. A new excipient or novel complexing system would increase development and regulatory burden.

What excipient strategy is appropriate for trimethoprim oral liquids?

Oral liquids offer the clearest commercial differentiation opportunity.

Ready-to-use oral solution

A true solution can provide excellent dose uniformity but is difficult to achieve if the drug concentration exceeds its practical solubility. pH adjustment, cosolvents, complexing agents, or a suitable salt form may be needed.

A solution product must control:

• Chemical stability
• Precipitation during storage
• pH drift
• Preservative effectiveness
• Container compatibility
• Palatability
• Dose accuracy

Ready-to-use products are attractive for caregivers because they eliminate reconstitution errors. They also reduce preparation steps in hospitals and pharmacies.

Powder for oral suspension

A powder for reconstitution reduces shipping weight and can improve shelf life before activation. It creates a separate in-use stability requirement after water is added.

A commercially viable product should provide:

• Clear reconstitution instructions
• Low foaming
• Rapid wetting
• Easy redispersion
• A measured oral-syringe presentation
• Stable concentration during the labeled in-use period

A powder product may be more practical than a ready-to-use suspension where cold-chain limitations, long distribution routes, or low-volume markets increase logistics costs.

Pediatric taste-masked suspension

A premium pediatric product would combine:

1. Taste-masked trimethoprim particles
2. A physically stable suspension vehicle
3. A low-sugar or sugar-free sweetener system
4. A child-acceptable flavor
5. An oral syringe with clear dose markings

Sugar-free systems may improve dental suitability and reduce concerns for diabetic patients, but polyols can cause gastrointestinal effects at higher exposure. Sodium-containing excipients may also matter for patients requiring sodium restriction.

The label should provide age-appropriate dosing devices and minimize dose-conversion errors. A formulation supplied at a concentration that matches common pediatric doses can reduce caregiver calculation burden.

What formulations are protected by trimethoprim patents?

The core trimethoprim molecule is an established generic compound. Its original composition-of-matter protection has expired in major markets. Current commercial protection is more likely to arise from product-specific formulation patents, process patents, trademarks, regulatory exclusivity, or contractual supply arrangements.

Potentially protectable formulation features include:

• A defined taste-masked trimethoprim particle
• A resin-drug complex with specified loading and release characteristics
• A stable aqueous or dispersed liquid at a defined pH
• A specific preservative and buffer system
• A low-sugar pediatric suspension
• A combination product with a defined ratio and release profile
• A manufacturing process that improves dissolution or content uniformity
• A container-closure system that improves in-use stability

Patentability will depend on novelty, nonobviousness, enablement, and claim scope. A generic suspension using well-known polymers, sweeteners, and preservatives is unlikely to create a strong exclusionary position without a demonstrated technical effect.

The stronger patent strategy is to claim a measurable product attribute, such as a defined dissolution profile, long in-use stability, controlled particle release, or improved taste performance supported by comparative data.

When does trimethoprim lose exclusivity?

Trimethoprim has already lost primary small-molecule exclusivity. Generic competition is established in the United States and other major markets. The commercial question is no longer whether generic entry is possible. It is whether a differentiated product can obtain market access and earn a margin against low-cost conventional products.

Exclusivity category	Current relevance
Composition-of-matter patent	Expired or commercially irrelevant
Basic use patents	Generally expired or weak against established generic use
Conventional tablet protection	Limited unless tied to a novel formulation
Formulation patents	Possible for new taste-masking, stability, or delivery systems
Regulatory exclusivity	Generally limited for a legacy generic product
Trademark protection	Potentially relevant for brand positioning
Supply and manufacturing barriers	Can be commercially important despite weak patent protection

For a new trimethoprim formulation, the principal entry barriers are likely to be formulation development, bioequivalence, manufacturing validation, product stability, and market access rather than the active ingredient patent estate.

What FDA regulatory issues affect a new trimethoprim product?

A conventional generic tablet may qualify for an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. A materially different dosage form, route, strength, or formulation may require a different regulatory strategy.

Key FDA considerations include:

• Reference-listed drug selection
• Strength and dosage-form equivalence
• Dissolution performance
• Inactive-ingredient precedent
• Pediatric excipient exposure
• Preservative effectiveness
• In-use stability
• Container and closure performance
• Oral syringe accuracy
• Drug-drug interaction risks from excipient systems
• Labeling for reconstitution and storage

The FDA Inactive Ingredient Database can help identify prior use of excipients by route, dosage form, and potency. It does not eliminate the need for formulation-specific safety and quality assessment (U.S. Food and Drug Administration, n.d.-a).

The FDA guidance on pharmaceutical quality and generic drug development supports a risk-based assessment of critical material attributes, manufacturing variables, dissolution, and product performance (U.S. Food and Drug Administration, 2019).

How strong is the patent estate for trimethoprim formulation opportunities?

The core estate is weak because the active ingredient is old and widely genericized. A new excipient-based product can still create a focused but narrow patent position.

Stronger patent opportunities

• Demonstrated taste masking without delayed systemic release
• Long-term suspension stability under temperature stress
• Reduced dosing error through concentration and device design
• Improved dissolution from a poorly soluble API
• A novel multiparticulate system suitable for pediatric administration
• A low-sodium or sugar-free product with preserved palatability
• A formulation compatible with decentralized or low-resource distribution

Weaker patent opportunities

• Routine use of a known sweetener
• Standard xanthan-gum suspension vehicles
• Conventional film coating
• Basic tablet excipient substitution
• Flavor changes without measured performance improvement
• A known excipient combination without unexpected results

Patent claims should be supported by comparative data against marketed products or conventional formulation controls. Relevant data may include bitterness scores, redispersion time, sedimentation volume, dissolution, chemical purity, microbial quality, and patient or caregiver usability.

Which commercial opportunities are most attractive?

Pediatric liquid products

This is the clearest opportunity. The product can compete through taste, concentration, ready-to-use convenience, dosing devices, and shelf stability. The addressable market is constrained by the clinical use of trimethoprim and by competition from trimethoprim-sulfamethoxazole, but a well-designed pediatric product can improve adherence and pharmacy differentiation.

Hospital and institutional products

Hospitals may value:

• Ready-to-administer liquids
• Unit-dose packaging
• Oral syringes
• Simplified storage
• Reduced compounding workload
• Consistent supply

A hospital product must show operational value because procurement is price-sensitive.

Low-resource and distribution-sensitive markets

Powder-for-suspension products, heat-stable packaging, and reduced reconstitution complexity may have commercial relevance in regions with limited pharmacy infrastructure. The product must be designed around local water quality, storage conditions, packaging availability, and dosing practices.

Combination products

Trimethoprim-sulfamethoxazole remains commercially important. Opportunities include pediatric fixed-dose suspensions, dispersible tablets, taste-masked products, and presentations optimized for weight-based dosing.

Combination products create more complex formulation and regulatory issues because the excipients must support both active ingredients. They also face established generic competition and may have narrower opportunities for meaningful differentiation.

Compounding and specialty pharmacy

A stable, standardized oral liquid could compete with extemporaneous compounding. The value proposition would depend on availability, beyond-use dating, concentration options, and reimbursement. A commercial product with validated stability may reduce preparation variability, but it must offer sufficient margin against pharmacy compounding.

What generic launch risks exist for a differentiated trimethoprim product?

The main risks are commercial rather than patent-based.

Risk	Business effect
Low-cost conventional tablets	Limits pricing power
Existing oral liquids	Raises differentiation threshold
Trimethoprim-sulfamethoxazole substitution	Reduces standalone demand
Pediatric market size	May not support complex manufacturing
Bioequivalence failure	Delays approval
Taste-masking release delay	Creates clinical and regulatory risk
Preservative or pH instability	Causes shelf-life failure
API variability	Affects dissolution and content uniformity
Low reimbursement	Compresses launch margins
Hospital formulary resistance	Slows adoption

A formulation that requires expensive coating, specialized equipment, or a novel excipient may not be economically viable unless it secures a premium channel or licensing partner.

How does trimethoprim compare with trimethoprim-sulfamethoxazole?

Factor	Trimethoprim	Trimethoprim-sulfamethoxazole
Formulation complexity	Lower	Higher because two APIs must remain stable and bioavailable
Standalone demand	More limited	Broader historical use
Taste-masking challenge	Significant	Significant, often more difficult
Pediatric opportunity	High for liquid products	High for weight-based combination dosing
Substitution pressure	High from combination therapy	High from other antibiotics and guideline changes
Patent opportunity	Formulation-focused	Ratio, release, taste, and combination formulation-focused
Safety and labeling burden	Lower than combination	Higher due to sulfonamide-related warnings and interactions

Trimethoprim alone may offer a simpler formulation platform. The combination product may offer a larger market but requires more complex development and faces more stringent product-performance comparisons.

What licensing and partnering opportunities exist?

Licensing value is most likely to arise from platform technology rather than trimethoprim rights. Relevant assets include:

• Taste-masking technology validated for bitter weak bases
• Pediatric suspension vehicles
• Long-term preservative systems
• Ready-to-use liquid manufacturing capacity
• Multiparticulate coating technology
• Oral-syringe and unit-dose packaging systems
• Regional distribution rights
• Combination-product development capability

A developer with a differentiated formulation may partner with a generic pharmaceutical company that already has regulatory infrastructure, API sourcing, and hospital distribution. The licensor’s negotiating position improves when the formulation has completed pivotal stability studies, demonstrated bioequivalence, and obtained patent filings covering specific performance characteristics.

Key Takeaways

• Trimethoprim’s active ingredient is a mature generic and has limited standalone patent value.
• The strongest commercial opportunity is a differentiated pediatric oral liquid.
• Taste masking, suspension stability, dosing accuracy, and ready-to-use convenience are the most valuable formulation targets.
• Conventional tablets can be competitive through manufacturing efficiency but are unlikely to command a substantial premium.
• Formulation patents require measurable technical effects, not routine excipient substitution.
• Trimethoprim-sulfamethoxazole offers a larger combination market but introduces greater formulation and regulatory complexity.
• FDA inactive-ingredient precedent, bioequivalence, in-use stability, and pediatric excipient exposure are central development issues.
• Commercial success will depend on channel selection, supply reliability, and a clear advantage over low-cost tablets and existing liquids.

FAQs

Can trimethoprim be formulated as a sugar-free pediatric suspension?

Yes. A sugar-free product can use high-intensity sweeteners, polyols, viscosity modifiers, flavors, and taste-masked drug particles. The formulation must control bitterness, gastrointestinal tolerability, preservative performance, and dose uniformity.

Is a trimethoprim oral solution commercially better than a suspension?

Not automatically. A solution can improve dose uniformity but may face solubility, precipitation, and taste challenges. A suspension may provide better drug loading and stability if it is easy to redisperse and administer.

Are novel excipients necessary for a differentiated trimethoprim product?

No. A differentiated product can use established excipients if the formulation produces a documented advantage. Novel excipients may improve performance but increase regulatory and safety requirements.

Can a trimethoprim formulation receive orphan-drug exclusivity?

Trimethoprim is generally used for common infections and is not an obvious orphan-drug candidate. Orphan designation depends on the specific disease, prevalence, clinical rationale, and regulatory eligibility.

What is the best first product for a trimethoprim formulation developer?

A taste-masked, ready-to-use pediatric suspension with a validated oral syringe and commercially practical shelf life is the most direct product concept. It addresses the main patient and caregiver barriers without requiring the manufacturing complexity of an advanced delivery system.

References

1. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry. https://www.fda.gov/

3. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. National Library of Medicine. (n.d.). DailyMed. https://dailymed.nlm.nih.gov/dailymed/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP-NF). United States Pharmacopeial Convention.